<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084015</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000668</org_study_id>
    <nct_id>NCT04084015</nct_id>
  </id_info>
  <brief_title>Early Insertion of Axillary Impella® With VA ECMO</brief_title>
  <official_title>Early Insertion of Axillary Impella® for LV Recovery in Patients With Veno-arterial Extracorporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is used as a rescue strategy for&#xD;
      patients in acute hemodynamic deterioration such as cardiogenic shock and cardiopulmonary&#xD;
      arrest with severe pulmonary congestion. VA ECMO is the fastest way to stabilize a patient&#xD;
      with cardiogenic shock and improve end-organ perfusion. However, one of the major&#xD;
      disadvantages of peripheral VA-ECMO is that it provides no left ventricular unloading and&#xD;
      increases left ventricular (LV) afterload secondary to the retrograde blood flow. Therefore,&#xD;
      LV wall tension and myocardial oxygen demand may actually increase in the setting of VA ECMO.&#xD;
&#xD;
      The Impella® device is a miniature rotary blood pump which can be inserted retrograde across&#xD;
      the aortic valve. In this configuration, it withdraws blood from the LV and ejects it into&#xD;
      the ascending aorta. It unloads the left ventricle, reducing LV wall tension and myocardial&#xD;
      oxygen demand and increasing myocardial blood flow. The Impella® 5.0 is an FDA approved pump&#xD;
      designed for intermediate support in patients with severe, cardiogenic shock. The axillary&#xD;
      positioning allows for early extubation and ambulation and is more stable than groin&#xD;
      placement.&#xD;
&#xD;
      In present practice, the decision to place an Impella® pump in VA-ECMO patients is based on&#xD;
      the perceived need for direct LV unloading or when a bridge device is required to transition&#xD;
      off ECMO support. Patients with peripheral VA ECMO are managed with inotropic agents at the&#xD;
      beginning and once patients develop pulmonary edema mechanical LV unloading is considered&#xD;
      electively. The advantage of LV unloading with Impella® has been demonstrated in recent&#xD;
      studies. We also reported that concomitant implantation of Impella® with VA ECMO for LV&#xD;
      unloading resulted in improved survival and recovery of ventricular performance in patients&#xD;
      with cardiogenic shock. Compared to delayed elective LV unloading, early LV unloading could&#xD;
      lead to decreased pulmonary edema, improved oxygenation delivery to the myocardium, increased&#xD;
      chance of LV recovery and improved survival.&#xD;
&#xD;
      The objective of this prospective study is to assess whether the early direct ventricular&#xD;
      unloading using axillary Impella® leads to higher rates of cardiac recovery, defined as&#xD;
      survival free from mechanical circulatory support, heart transplantation or inotropic support&#xD;
      at thirty days, compared with the conventional, elective placement of Impella® after&#xD;
      developing significant pulmonary congestion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single-arm trial will include all consecutive patients undergoing&#xD;
      cannulation of peripheral VA ECMO at the Massachusetts General Hospital (MGH) from April 2019&#xD;
      to March 2020. All enrolled patients will undergo surgical placement of Impella® via axillary&#xD;
      artery within 48 hours after peripheral VA ECMO initiation and be managed with early&#xD;
      extubation and ambulation strategy.&#xD;
&#xD;
      After Impella® placement, there will be no research procedures performed. Subjects will&#xD;
      receive standard of care and the subject's progress will be documented throughout the 30 days&#xD;
      study follow-up. The data obtained from the electronic medical record in Epic health record&#xD;
      system at MGH will be reviewed throughout the study.&#xD;
&#xD;
      The primary outcome of this study will be survival at 30 days. Prespecified secondary end&#xD;
      points will include the rate of death from cardiovascular causes, New York Heart Association&#xD;
      (NYHA) functional class, LV function (assessed by echocardiography), and the rate of stroke,&#xD;
      neurological functional status, acute kidney injury, vascular complications, and bleeding.&#xD;
&#xD;
      The enrolled subjects (early Impella®) would be compared with patients who underwent current&#xD;
      elective placement of Impella® after cannulation of VA ECMO (elective Impella®) in the past&#xD;
      two years. Student's t-test (for continuous variables) or Fisher exact test (for categorical&#xD;
      variables) will be used for between-group comparisons. The primary endpoint in the data&#xD;
      analysis is binary: 30-day survival. The null hypothesis of no difference between early&#xD;
      Impella® and elective Impella® will be tested using logistic regression. The secondary&#xD;
      endpoint, the rate of death from cardiovascular causes, NYHA functional class, LV function,&#xD;
      and the rate of stroke, neurological functional status, acute kidney injury, vascular&#xD;
      complications, and bleeding, will be addressed using competing risks hazard regression&#xD;
      models. This is a pilot study for the future multicenter study. If this study demonstrates no&#xD;
      inferiority or any significant superiority, we will proceed to do multicenter prospective&#xD;
      study. Power analysis will be assessed based on the result of this preliminary study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely stopped since enrollment was much slower than initially expected.&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This prospective, single-arm trial will include all consecutive patients undergoing cannulation of peripheral VA ECMO at the Massachusetts General Hospital from April 2019 to March 2020. Approximately 20 subjects are anticipated to be enrolled during this time.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days after cannulation of VA ECMO</time_frame>
    <description>Patient survival at 30-days post VA ECMO cannulation timepoint. Collected through patient chart review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death From Cardiovascular Causes</measure>
    <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
    <description>Death from cardiovascular cases at 30-days post VA ECMO cannulation timepoint. Collected from review of patient charts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association Functional Status</measure>
    <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
    <description>Retrospective review in a patient chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Neurological Event</measure>
    <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
    <description>Neurological event up to 30-days post VA-ECMO cannulation or Discharge. Includes hypoxic brain damage, intracerebral bleeding, hemorrhagic stroke, or ischemic stroke. Data collected through patient chart review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Function</measure>
    <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
    <description>Measured by Echocardiogram study.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Acute Kidney Injury</measure>
    <time_frame>Within 30 days after cannulation of VA ECMO</time_frame>
    <description>Retrospective review in a patient chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Vascular Complication</measure>
    <time_frame>Within 30 days after cannulation of VA ECMO</time_frame>
    <description>Retrospective review in a patient chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Bleeding</measure>
    <time_frame>Within 30 days after cannulation of VA ECMO</time_frame>
    <description>Moderate bleeding in hospital. Defined by transfusion of red blood cells without hemodynamic impairment. Collected through review of patient chart.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Early axillary Impella®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Axillary Impella®</intervention_name>
    <description>All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
    <arm_group_label>Early axillary Impella®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Impaired LV systolic function with ≤35% of left ventricular ejection fraction (LVEF)&#xD;
&#xD;
          -  Enlarged LV with ≥50mm of left ventricular diastolic diameter (LVEDD) on&#xD;
             echocardiogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-cardiac etiology&#xD;
&#xD;
          -  Surgically correctable cardiac abnormality&#xD;
&#xD;
          -  Recent significant pulmonary embolism&#xD;
&#xD;
          -  Severe pulmonary hypertension&#xD;
&#xD;
          -  Acute aortic dissection&#xD;
&#xD;
          -  Presence of mechanical aortic valve prosthesis&#xD;
&#xD;
          -  Presence of left ventricle thrombus&#xD;
&#xD;
          -  Pre-existing Impella® 5.0&#xD;
&#xD;
          -  Critical aortic stenosis&#xD;
&#xD;
          -  Uncorrectable system malperfusion under ECMO support&#xD;
&#xD;
          -  Significant cerebrovascular accident&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David D'Alessandro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <results_first_submitted>April 5, 2021</results_first_submitted>
  <results_first_submitted_qc>June 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David A. D'Alessandro, M.D.</investigator_full_name>
    <investigator_title>Associate Professor, Principal Investigator, Surgical Director, Heart Transplantation and Mechanical Circulatory Support</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal membrane oxygenation</keyword>
  <keyword>Left ventricular unloading</keyword>
  <keyword>Impella®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Neither identifiable nor non-identifiable data will be sent outside Partners or to Partners researchers not listed on the protocol.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT04084015/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from inpatient medical units at Massachusetts General Hospital. The recruitment period was from August 2019-March 2021.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Early Axillary Impella®</title>
          <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Axillary Impella®</title>
          <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Patient survival at 30-days post VA ECMO cannulation timepoint. Collected through patient chart review.</description>
        <time_frame>30 days after cannulation of VA ECMO</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Patient survival at 30-days post VA ECMO cannulation timepoint. Collected through patient chart review.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death From Cardiovascular Causes</title>
        <description>Death from cardiovascular cases at 30-days post VA ECMO cannulation timepoint. Collected from review of patient charts.</description>
        <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Death From Cardiovascular Causes</title>
          <description>Death from cardiovascular cases at 30-days post VA ECMO cannulation timepoint. Collected from review of patient charts.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association Functional Status</title>
        <description>Retrospective review in a patient chart</description>
        <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
        <population>Data were not collected. NYHA Assessment was not done at 30-days post VA-ECMO cannulation per standard of care.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association Functional Status</title>
          <description>Retrospective review in a patient chart</description>
          <population>Data were not collected. NYHA Assessment was not done at 30-days post VA-ECMO cannulation per standard of care.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Neurological Event</title>
        <description>Neurological event up to 30-days post VA-ECMO cannulation or Discharge. Includes hypoxic brain damage, intracerebral bleeding, hemorrhagic stroke, or ischemic stroke. Data collected through patient chart review.</description>
        <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Neurological Event</title>
          <description>Neurological event up to 30-days post VA-ECMO cannulation or Discharge. Includes hypoxic brain damage, intracerebral bleeding, hemorrhagic stroke, or ischemic stroke. Data collected through patient chart review.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Function</title>
        <description>Measured by Echocardiogram study.</description>
        <time_frame>30 days after cannulation of VA ECMO or Discharge</time_frame>
        <population>Neither of the subjects who were enrolled had an echocardiogram done at the 30 day post VA-ECMO cannulation or Discharge timepoints so LVEF could not be collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Function</title>
          <description>Measured by Echocardiogram study.</description>
          <population>Neither of the subjects who were enrolled had an echocardiogram done at the 30 day post VA-ECMO cannulation or Discharge timepoints so LVEF could not be collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Acute Kidney Injury</title>
        <description>Retrospective review in a patient chart</description>
        <time_frame>Within 30 days after cannulation of VA ECMO</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Kidney Injury</title>
          <description>Retrospective review in a patient chart</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vascular Complication</title>
        <description>Retrospective review in a patient chart</description>
        <time_frame>Within 30 days after cannulation of VA ECMO</time_frame>
        <population>Data not collected for either subject</population>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Complication</title>
          <description>Retrospective review in a patient chart</description>
          <population>Data not collected for either subject</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Bleeding</title>
        <description>Moderate bleeding in hospital. Defined by transfusion of red blood cells without hemodynamic impairment. Collected through review of patient chart.</description>
        <time_frame>Within 30 days after cannulation of VA ECMO</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Axillary Impella®</title>
            <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding</title>
          <description>Moderate bleeding in hospital. Defined by transfusion of red blood cells without hemodynamic impairment. Collected through review of patient chart.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected up to 30-days post VA-ECMO cannulation/Impella Insertion, whichever came first.</time_frame>
      <desc>Each subject will be followed through 30 days post VA-ECMO cannulation/Impella Insertion. Adverse events data will be collected throughout this time period. Adverse events will be determined and assessed only through medical chart review.</desc>
      <group_list>
        <group group_id="E1">
          <title>Early Axillary Impella®</title>
          <description>Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO&#xD;
Axillary Impella®: All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Subject death during 30-day follow-up period. It was expected/unrelated to the study.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David D'Alessandro</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-8841</phone>
      <email>DADALESSANDRO@MGH.HARVARD.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

